
Surmodics SRDX
Quartalsbericht 2025-Q2
hinzugefügt 08.08.2025
Surmodics Kurzfristige Verbindlichkeiten 2011-2026 | SRDX
Kurzfristige Verbindlichkeiten Jährlich Surmodics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.5 M | 24 M | 32.1 M | 29.8 M | 18.9 M | 20.2 M | 35.1 M | 9.8 M | 10.1 M | 4.7 M | 4.07 M | 5.98 M | 6.9 M | 11 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 35.1 M | 4.07 M | 16.7 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Diagnostik & Forschung
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
1.71 B | $ 114.25 | -1.07 % | $ 34.7 B | ||
|
Anixa Biosciences
ANIX
|
1.97 M | $ 2.64 | 3.53 % | $ 85.7 K | ||
|
Biodesix
BDSX
|
14.3 M | $ 15.55 | 3.19 % | $ 2.02 B | ||
|
Biomerica
BMRA
|
1.74 M | $ 2.17 | - | $ 4.98 M | ||
|
BioNano Genomics
BNGO
|
22.9 M | $ 1.2 | -0.03 % | $ 6.53 M | ||
|
Burning Rock Biotech Limited
BNR
|
372 M | $ 16.5 | 1.85 % | $ 178 M | ||
|
Aspira Women's Health
AWH
|
3.46 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
5.51 M | - | -13.05 % | $ 7.29 M | ||
|
CareDx, Inc
CDNA
|
89.8 M | $ 18.32 | 0.05 % | $ 976 M | ||
|
Celcuity
CELC
|
44.2 M | $ 113.8 | 1.04 % | $ 5.32 B | ||
|
Check-Cap Ltd.
CHEK
|
1.81 M | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
3.54 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Charles River Laboratories International
CRL
|
1.12 B | $ 168.44 | -3.13 % | $ 8.35 B | ||
|
Castle Biosciences
CSTL
|
49.4 M | $ 24.85 | 0.04 % | $ 690 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
13.8 M | - | - | $ 562 M | ||
|
Quest Diagnostics Incorporated
DGX
|
2.28 B | $ 197.89 | 0.37 % | $ 22 B | ||
|
Danaher Corporation
DHR
|
6.81 B | $ 190.62 | -0.26 % | $ 136 B | ||
|
DexCom
DXCM
|
2.14 B | $ 62.7 | 0.76 % | $ 24.5 B | ||
|
Akumin
AKU
|
169 M | - | -17.87 % | $ 25.9 M | ||
|
Fulgent Genetics
FLGT
|
72.9 M | $ 16.8 | -0.15 % | $ 508 M | ||
|
Accelerate Diagnostics
AXDX
|
66.6 M | - | -61.36 % | $ 2.46 M | ||
|
Guardant Health
GH
|
303 M | $ 92.35 | -1.58 % | $ 11.6 B | ||
|
Global Cord Blood Corporation
CO
|
647 M | - | - | $ 399 M | ||
|
ICON Public Limited Company
ICLR
|
2.8 B | $ 110.38 | -3.34 % | $ 9.1 B | ||
|
Interpace Biosciences
IDXG
|
5.1 M | $ 1.96 | 5.82 % | $ 8.67 M | ||
|
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | ||
|
Illumina
ILMN
|
1.55 B | $ 127.63 | 0.2 % | $ 20.3 B | ||
|
Exact Sciences Corporation
EXAS
|
641 M | - | - | $ 19.8 B | ||
|
IQVIA Holdings
IQV
|
8.34 B | $ 168.24 | -2.9 % | $ 28.9 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.27 B | - | - | $ 10.7 B | ||
|
Laboratory Corporation of America Holdings
LH
|
2.82 B | $ 274.94 | 0.41 % | $ 22.9 B | ||
|
DermTech
DMTK
|
13.4 M | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
333 M | $ 76.0 | -0.14 % | $ 5.13 B | ||
|
Medpace Holdings
MEDP
|
1.34 B | $ 485.89 | -2.5 % | $ 14 B | ||
|
Enzo Biochem
ENZ
|
24.8 M | - | -8.98 % | $ 14.8 K | ||
|
Mettler-Toledo International
MTD
|
1.2 B | $ 1 258.2 | -0.3 % | $ 25.9 B | ||
|
Myriad Genetics
MYGN
|
134 M | $ 4.84 | 1.79 % | $ 448 M | ||
|
ENDRA Life Sciences
NDRA
|
751 K | $ 4.69 | - | $ 3.69 M | ||
|
NeoGenomics
NEO
|
88.3 M | $ 8.06 | 0.75 % | $ 1.03 B | ||
|
Neogen Corporation
NEOG
|
174 M | $ 9.42 | 0.11 % | $ 2.04 B | ||
|
National Research Corporation
NRC
|
36.6 M | $ 17.35 | 1.11 % | $ 388 M | ||
|
Natera
NTRA
|
310 M | $ 207.01 | -0.46 % | $ 20.4 B | ||
|
Pacific Biosciences of California
PACB
|
72.8 M | $ 1.36 | 1.49 % | $ 408 M | ||
|
Precipio
PRPO
|
3.75 M | $ 25.23 | -1.29 % | $ 40.5 M | ||
|
Personalis
PSNL
|
31.1 M | $ 6.63 | 0.76 % | $ 393 M | ||
|
RadNet
RDNT
|
587 M | $ 55.12 | 0.6 % | $ 4.14 B |